CD19 and neoplasm: Hence, while retaining potent killing capacities against CD19+ tumor cells in combination with secretion of expected cytokines upon antigen sensitization, these esCAR T cells harbor valuable selection features for simplified manufacturing protocols and the potential for specific in vivo depletion.